Planning target volume as a predictor of disease progression in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy and concurrent and/or sequential immune checkpoint inhibition.
Julian TaugnerLukas KäsmannMonika KarinChukwuka EzeBenedikt FlörschJulian GuggenbergerMinglun LiAmanda TufmanNiels ReinmuthThomas DuellClaus BelkaFarkhad ManapovPublished in: Investigational new drugs (2021)
In this prospective analysis of inoperable stage III NSCLC patients treated with definitive CRT combined with concurrent and/or sequential CPI, significantly shorter PFS and eMFS were observed in patients with initial PTV ≥ 900ccm.